Navigation Links
Another JDRF partner moves research forward with collaboration agreement for diabetes treatment
Date:6/18/2009

NEW YORK, June 18, 2009 The Juvenile Diabetes Research Foundation said today that for the fourth time in 18 months, one of its biotech partners has signed a collaboration agreement with a large pharmaceutical company to move research on type 1 diabetes into the final phases of trials.

According to JDRF, a leader in setting the agenda for diabetes research worldwide and the largest charitable funder and advocate of type 1 diabetes research, the development is the latest success in its innovative Industry Discovery and Development Partnership (IDDP) program, through which JDRF provides early stage research funding to biotech companies working on technologies and therapeutic candidates.

In the most recent success, JDRF industry partner Bayhill Therapeutics Inc., based in California, entered into a collaboration agreement with Genentech, Inc., a wholly owned member of the Roche Group, to further develop and potentially commercialize a novel antigen-specific immunotherapeutic designed to reverse the immune response that causes type 1 diabetes.

To date, JDRF has awarded more than $29 million in research funding to 25 companies through its IDDP program. JDRF supported the ongoing Bayhill clinical trial with an IDDP grant in October of 2008.

"We began the IDDP program to help small companies demonstrate proof-of-principle for innovative ideas and products to treat and cure type 1 diabetes, in order to attract funding for potential commercialization from large drug companies," said Alan J. Lewis, PhD, President and Chief Executive Officer of JDRF. "This latest agreement further demonstrates that the strategy is successful in accelerating the pace of research leading to a cure for diabetes."

Dr. Lewis noted that the development underscores JDRF's unique role helping to accelerate and translate research discoveries into cures and better treatment of type 1 diabetes and its complications. By supporting early stage research at small biotech companies, JDRF looks to lower the risk for larger pharmaceutical companies to create biotech partnerships and carry the products through expensive, late-stage trials and regulatory approvals. The goal, he said, is to bring cures and treatments for type 1 diabetes to market faster.

Other IDDP partners that have created similar agreements include: Tolerx, based in Massachusetts, which has joined with GlaxoSmithKline to develop an anti-CD3 antibody to preserve beta cell function in newly diagnosed patients; Maryland-based MacroGenics, which is developing a similar antibody with Lilly; and Canada's Transition Therapeutics, which has signed a commercialization agreement for a beta cell regenerative therapy with Lilly.

Bayhill's BHT-3021 compound is now in Phase I/II clinical trials supported by JDRF, is a plasmid encoding proinsulin designed to target specific pathogenic immune cells involved in the immune response of type 1 diabetes.


'/>"/>

Contact: William Ahearn
wahearn@jdrf.org
212-479-7531
Juvenile Diabetes Research Foundation International
Source:Eurekalert

Related biology news :

1. One species entire genome discovered inside anothers
2. Same gene protects from 1 disease, opens door to another
3. Another type of nanotube, a how-to guide to making bamboo-structured carbon nanotubes
4. For good or ill Ireland gains another mammal species
5. Ocean acidification -- another undesired side effect of fossil fuel-burning
6. Viral recombination another way HIV fools the immune system
7. Arctic ice on the verge of another all-time low
8. Another fisheries commission throws the science overboard in tuna decision, WWF says
9. Another reason to drink a nice cup of shade-grown joe
10. Cancer: Another step towards medication
11. Desert woodrats switch one dietary poison for another
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/15/2016)... April 15, 2016  A new partnership announced ... accurate underwriting decisions in a fraction of the ... priced and high-value life insurance policies to consumers ... With Force Diagnostics, rapid testing (A1C, Cotinine ... readings (blood pressure, weight, pulse, BMI, and activity ...
(Date:3/31/2016)... PROVIDENCE, R.I. , March 31, 2016  Genomics ... leadership of founding CEO, Barrett Bready , M.D., ... addition, members of the original technical leadership team, including ... Vice President of Product Development, Steve Nurnberg and Vice ... have returned to the company. Dr. Bready ...
(Date:3/21/2016)... -- Unique technology combines v ...   Xura, Inc. (NASDAQ: ... communications services, today announced it is working alongside SpeechPro ... particularly those in the Financial Services Sector, the ability ... a mobile app, alongside, and in combination with, traditional ...
Breaking Biology News(10 mins):
(Date:4/27/2016)... 27, 2016 MedDay, a biotechnology company ... the appointment of Catherine Moukheibir as Chairman of its Board ... Jean Jacques Garaud , who contributed to the rapid ... immediately. Catherine started her career in strategy consulting ... London .  She held C-Suite level roles ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice ... electrical, mechanical and electromechanical patent applications. He has an electrical engineering and computer ...
(Date:4/26/2016)... , ... April 26, 2016 , ... The European ... been selected as one of three finalists for the European Inventor Award 2016 in ... innovation prize will be announced at a ceremony in Lisbon on June 9th. , ...
(Date:4/26/2016)... ... 2016 , ... Mr. Palmer created the RPO business for Ceridian and lead ... managed services contract in the U.S. intelligence community with The SI (a Lockheed Martin ... Younger, founder of Accolo. “We are growing and his experience guiding our expansion ...
Breaking Biology Technology: